Want to join the conversation?
$GILD said that non-GAAP product GM was 87.2% for 1Q16 vs. 90.9% in 1Q15. The dip in GM reflects a $200MM charge or $0.12 EPS related to the jury verdict in the Merck trial in March. The company posted non-GAAP R&D expenses of $769MM, a rise of 18% vs. 1Q15 due to the continued progression of clinical studies.
$DB is going to cut off services for about 3,400 clients in equities trading.
$F stock slid more than 2% after the company issued two safety recalls involving more than 650,000 Ford Fusion and Lincoln MKZ model cars.
The new CEO of $SBUX, Kevin Johnson, has some pretty large shoes to fill but there are many who have good faith in his ability to do so.
$TSLA opening a showroom in Michigan. A bold move !!